Bristol-Myers Aktie - Fundamentalanalyse - Dividendenrendite KGV

Bristol-Myers (ISIN: US1101221083, WKN: 850501) Kursdatum: 19.06.2018 Kurs: 53,640 USD
Beschreibung Daten
Symbol BMY
Marktkapitalisierung 88.613.281.792,00 USD
Land Vereinigte Staaten von Amerika
Indizes S&P 500
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits 2001-08-07 - 1000000.0000/951777.0000 | 1999-03-01 - 2.0000/1.0000 | 1997-03-03 - 2.0000/1.0000 | 1987-06-10 - 2.0000/1.0000 | 1983-05-27 - 2.0000/1.0000 | 1977-05-31 - 2.0000/1.0000 |
Internet www.bms.com
Letztes Bilanz Update 21.02.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 19.06.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
21,00 16,80 2,93% 3,00 34,99 87,93 4,27 7,55

Firmenbeschreibung

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company\'s products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.bms.com